Vitrification Versus Slow Freezing of Human Day 3 Embryos

NCT ID: NCT00710723

Last Updated: 2008-07-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

901 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-10-31

Study Completion Date

2008-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In assisted reproduction technology (ART), cryopreservation of embryos maximizes the potential of IVF cycles. Currently different cryopreservation methods are used, the conventional slow freezing method and vitrification. There is, therefore an immediate need to assess which cryopreservation technique is preferential in human IVF. In this prospective randomised study conventional slow freezing and vitrification, using the Hemi-straw carrier system, of human day 3 embryos were compared.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. Background

Although there are studies that reported successful pregnancies after transfer of vitrified cleavage stage embryos, most of the studies focused on the vitrification of oocytes and blastocysts. As far as we know, there is only one report of a randomised prospective study were both common freezing methods -conventional slow freezing and vitrification (making use of the nylon loop system with 40% ethylene glycol), were compared for day 3 embryos (Rama Raju, Haranath et al., 2005). They report an implantation and pregnancy rate (14,9% and 35,0% respectively) with vitrification, which is significantly higher than the rates with the slow freezing protocol (4,2% and 17,4% respectively). There is still need to more randomised studies which compares both freezing methods for cleavage stage embryos .

There is evidence in literature that the vitrification method used at LUFc (hemi-straw) is superior to the method used in the randomised trial of Rama Raju. Liebermann and Tucker compared both the hemi-straw and cryoloop system for vitrification of day 3 embryos derived from abnormally fertilized zygotes (Liebermann and Tucker, 2002). They found no statistical difference (p=0.07) in the survival rate, but the development after 24 hours was statistically better (p =0.002) using hemi-straws. Based on this study we would even expect better results than the study of Rama Raju.

To further refine the effect of cryopreservation of cleavage stage embryos using the hemi-straw system on developmental and implantation potential, the effectiveness of vitrification (20% EG and 20% DMSO) was compared with slow freezing.
2. Materials and methods

* Patients In this prospective study all patients underwent IVF or ICSI between are included. Fresh embryo transfer was carried out on day 3 after insemination. All surplus embryos who reached at least the 6 cell stage on day 3 and had less than 20% fragmentation were considered for cryopreservation using either vitrification or slow freezing.
* Randomisation All embryos will be cryopreserved by one of the two methods. Randomisation will take place at day 3 after insemination. For practical reasons, all embryos frozen on the same day will be randomly assigned to the same freezing method.
* Results from retrospective data analysis Vitrification has been used as a standard cryopreservation method at the LUFc since September 2004. So both slow freezing and vitrification had been used for cryopreservation of day 3 embryos. The method used depends on workload… so there was no randomisation. After a retrospective analysis of these data (124 cycles 43 in the slow group and 81 in the vitrification group), we noticed a significant increase in the survival of the embryos after vitrification (81.2% in the vitrification group versus 45.8% in the slow group; p\<0.0001). There was no significant difference in pregnancy rate between both groups (19.8% in the vitrification versus 30.2% in slow group; p=NS).

So far we saw a remarkable difference in survival immediately or 24h after thawing, but a clear difference in the implantation rate has not been discovered yet, therefore we would like to start a randomised trial to proof a significant difference at the implantation or pregnancy level.
* Vitrification of human embryos Our method was based on the procedure described by Vanderzwalmen et al 2000 (Vanderzwalmen, Bertin et al., 2000). First the embryos were equilibrated (PBS with 17% HSA ) for 2 min at room temperature. They were then transferred to the first vitrification solution (PBS + 14% HSA + 10% DMSO + 10% ethylene glycol) for 2 min at RT followed by 30 sec in the second vitrification solution (PBS + 12% HSA + 20 % DMSO + 20% ethylene glycol + ficoll + sucrose). Finally the embryos were loaded as quickly as possible on the Hemi-straw in a droplet of approximately 3 µl and immersed directly in liquid nitrogen. Afterwards the hemi-straw was inserted in the CBS-straw.
* Thawing after vitrification The hemi-straw holding exactly one embryo was pulled out of the CBS straw and immediately immersed into 3 ml of the first thawing solution (PBS with 20% HSA) for 3 min at 36°C. Afterwards the embryo was consecutively exposed for 2 min to the 3 other thawing solutions (0.5M sucrose, 0.25M sucrose and 0.125M sucrose respectively). The embryos were washed thoroughly and incubated overnight in COOK blastocyst medium. Embryos are considered as 'survived' if at least 50% of the blastomeres survived the vitrification procedure.
* Slow freezing and thawing procedure For the slow freezing and thawing procedure we used the HEPES-buffered commercial freezing medium of Cook (K-SICS 5000) with propandiol and sucrose as cryoprotectants.
3. Statistical analysis and power calculation

Based on literature (Rama Raju et al 2005) we expect a 10 % higher implantation rate in the vitrification group (25%) versus the slow freezing group (15%)(Rama Raju, Haranath et al., 2005). To proof a significant difference at the implantation or pregnancy level with α=0,05 and a power (β) of 0,80. Therefore we would need 270 embryos transferred in each group.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cleavage Stage, Ovum

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

vitrification

Group Type EXPERIMENTAL

vitrification

Intervention Type PROCEDURE

Vitrification using Hemi-straw carrier system.

2

Slow freezing

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

vitrification

Vitrification using Hemi-straw carrier system.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Embryos of sufficient embryo quality: at least 6 cells on day 3 and less than 20 % fragmentation.
Minimum Eligible Age

18 Years

Maximum Eligible Age

43 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Gasthuisberg

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

University Hospital, Gasthuisberg.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

D'Hooghe Thomas, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

UZ Leuven

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UZ Leuven

Leuven, , Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

dwille1

Identifier Type: -

Identifier Source: org_study_id